The Anti-Inflammatory and Antioxidant Properties of Salidroside

Inflammation and oxidative stress are closely connected biological processes. Both are essential to normal physiology, but persistent inflammation and an ongoing imbalance between reactive oxygen species (ROS) and the body’s antioxidant defenses can damage cells and tissues.^[1,2] This overlap has prompted researchers to study compounds that may influence both processes.

One such compound is salidroside, a phenylethanoid glycoside found in plants of the Rhodiola genus, including Rhodiola rosea.^[3,4] Preclinical research has examined its potential neuroprotective, cardiovascular, metabolic, anti-inflammatory, and antioxidant effects.^[4]

Rather than acting only as a conventional antioxidant that reacts directly with free radicals, salidroside appears to affect cellular signaling pathways involved in antioxidant defenses, inflammation, and mitochondrial function. Most of this evidence, however, comes from cell and animal studies, not large human clinical trials.

What Is Salidroside?

Salidroside, also known as rhodioloside, is a naturally occurring compound associated with Rhodiola species. Chemically, it is a phenylethanoid glycoside and is closely related to tyrosol, another constituent found in Rhodiola.

Rhodiola rosea has a long history of traditional use and is often described as an adaptogenic plant. Modern pharmacological research has identified salidroside as one of several compounds that may contribute to the biological activity of Rhodiola extracts.^[4,5] For a closer look at how these constituents differ, read What Salidroside Is and How It Differs from Rosavins.

Purified salidroside should not be treated as interchangeable with Rhodiola rosea. A plant extract contains many compounds, and its composition can vary with the species, growing conditions, processing methods, and standardization. Findings from experiments using purified salidroside therefore describe the compound itself and do not necessarily predict the effects of a particular Rhodiola supplement.

Salidroside and Oxidative Stress

ROS are chemically reactive molecules generated during normal cellular metabolism. At controlled levels, they participate in cell signaling, immune defense, and physiological adaptation. Oxidative stress occurs when ROS production exceeds the capacity of antioxidant and repair systems to manage the resulting damage.

Excessive oxidative stress can damage proteins, DNA, and cell membranes. It can also impair mitochondrial function and activate inflammatory signaling. The body’s antioxidant network includes enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GSH-Px), along with nonenzymatic antioxidant molecules.

In experimental models, salidroside has been associated with lower markers of oxidative damage and greater activity or expression of endogenous antioxidant systems. For example, a study using a mouse model of hypoxia-related liver injury found that salidroside reduced ROS and malondialdehyde, a marker of lipid peroxidation, while increasing SOD, catalase, and GSH-Px activity.^[6] Cell-based experiments within the same study also implicated Nrf2, a transcription factor that regulates antioxidant-response genes.^[6]

These findings support a possible indirect antioxidant role through cellular defense pathways. They do not establish that salidroside produces the same effects in humans.

Salidroside and Inflammation

Oxidative stress and inflammation can reinforce one another. Immune cells produce ROS as part of normal defense, but excessive ROS can activate inflammatory pathways and increase the production of inflammatory mediators. Persistent inflammation can then generate additional oxidative stress, creating a self-reinforcing cycle.

Across preclinical models, salidroside has been associated with lower levels of inflammatory mediators such as tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). The exact result depends on the model, dose, tissue, and experimental conditions. One pathway frequently examined in this research is nuclear factor kappa B (NF-κB).

Targeting NF-κB Signaling

NF-κB is a family of transcription factors that helps regulate immune and inflammatory responses. When activated by infection, cellular stress, or tissue damage, NF-κB can increase the expression of numerous inflammation-related genes. Dysregulated or persistent NF-κB activity is involved in many chronic inflammatory conditions.^[7,8]

Under experimental conditions, salidroside has suppressed excessive activation of this pathway. In a mouse model of allergic airway inflammation, salidroside reduced inflammatory responses while inhibiting NF-κB activation and phosphorylation of p38 mitogen-activated protein kinase (MAPK).^[9]

MAPKs are another family of signaling proteins involved in cellular responses to stress and inflammation. Reported effects on NF-κB and MAPK pathways may help explain why salidroside has altered multiple inflammatory mediators in preclinical studies rather than affecting only one cytokine. These mechanistic findings remain model-specific and should not be interpreted as proof of clinical efficacy.

Mitochondria: Another Potential Link

Mitochondria generate most cellular ATP, but they also participate in redox signaling, inflammation, and programmed cell death. Dysfunctional mitochondria can become an important source of excessive ROS.

Salidroside has been associated with preserved mitochondrial structure or function in several cell and animal models.^[10–12] Depending on the experimental context, proposed mechanisms have included mitochondrial biogenesis, mitophagy, and signaling involving AMPK, SIRT1, or PGC-1α. These pathways should not be presented as a single, universally established mechanism because different studies have examined different tissues and injury models.

Protecting mitochondria could reduce excess ROS generation, while stronger antioxidant defenses could limit oxidative damage to mitochondria. This relationship may help connect the compound’s reported antioxidant and anti-inflammatory effects. For more on related brain pathways, see Mechanisms of Salidroside in the Brain: Neuroprotection, Anti-Fatigue, and Stress-Response Modulation.

What Could This Mean for Human Health?

The combination of antioxidant and anti-inflammatory activity has made salidroside a subject of research in experimental models of cardiovascular disease, neurological disorders, diabetes, kidney disease, liver injury, inflammatory conditions, and tissue fibrosis.^[4,13]

A 2026 systematic review and meta-analysis evaluated 14 preclinical studies involving 257 animals with diabetic nephropathy. The pooled findings associated salidroside with improvements in several measures of kidney function, antioxidant capacity, and inflammatory signaling. The authors also reported substantial heterogeneity and limitations in the underlying animal studies, so the results cannot establish effectiveness in people with diabetic kidney disease.^[14]

Researchers have also explored salidroside in cell and animal models related to rheumatoid arthritis.^[15,16] That work is preliminary. It does not show that salidroside prevents or treats rheumatoid arthritis in humans, and it should not be used as a substitute for evidence-based medical care.

Biological Activity Is Not the Same as Proven Clinical Effectiveness

Most evidence supporting salidroside’s antioxidant and anti-inflammatory properties comes from cultured cells and animal models. These studies can identify possible mechanisms and generate hypotheses, but they cannot determine whether people will experience the same effects.

Researchers still need well-designed human trials to clarify oral absorption, metabolism, tissue exposure, effective dosing, safety, drug interactions, and long-term outcomes. Studies of whole Rhodiola rosea extracts should also not be treated as clinical evidence for purified salidroside because the preparations are chemically different.

This distinction also matters when discussing stress and adaptogenic effects. Our article on salidroside and the HPA axis examines the relevant stress-response pathways and the limits of the available evidence.

Conclusion

Salidroside is a biologically active Rhodiola constituent with a compelling preclinical research profile. In cell and animal studies, it has influenced endogenous antioxidant systems, inflammatory signaling pathways such as NF-κB and MAPKs, and aspects of mitochondrial function. These findings offer plausible explanations for the protective effects reported across diverse experimental models.

The evidence remains weighted heavily toward preclinical research. Salidroside should therefore be viewed as a promising research compound, not an established treatment for inflammatory or oxidative-stress-related disease. Carefully controlled human trials are needed to determine whether its mechanistic effects translate into meaningful clinical benefits.

 

References

1. Orlando FA, Mainous AG. Inflammation and chronic disease. Front Med (Lausanne). 2024;11:1434533. doi:10.3389/fmed.2024.1434533
2. Reddy VP. Oxidative stress in health and disease. Biomedicines. 2023;11(11):2925. doi:10.3390/biomedicines11112925
3. Palmeri A, Mammana L, Tropea MR, Gulisano W, Puzzo D. Salidroside, a bioactive compound of Rhodiola rosea, ameliorates memory and emotional behavior in adult mice. J Alzheimers Dis. 2016;52(1):65-75. doi:10.3233/JAD-151159
4. Zhang X, Xie L, Long J, et al. Salidroside: A review of its recent advances in synthetic pathways and pharmacological properties. Chem Biol Interact. 2021;339:109268. doi:10.1016/j.cbi.2020.109268
5. Ivanova Stojcheva E, Quintela JC. The effectiveness of Rhodiola rosea L. preparations in alleviating various aspects of life-stress symptoms and stress-induced conditions: Encouraging clinical evidence. Molecules. 2022;27(12):3902. doi:10.3390/molecules27123902
6. Xiong Y, Wang Y, Xiong Y, Teng L. Protective effect of salidroside on hypoxia-related liver oxidative stress and inflammation via Nrf2 and JAK2/STAT3 signaling pathways. Food Sci Nutr. 2021;9(9):5060-5069. doi:10.1002/fsn3.2459
7. Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-κB pathway for the therapy of diseases: Mechanism and clinical study. Signal Transduct Target Ther. 2020;5:209. doi:10.1038/s41392-020-00312-6
8. Mao H, Zhao X, Sun S. NF-κB in inflammation and cancer. Cell Mol Immunol. 2025;22:811-839. doi:10.1038/s41423-025-01310-w
9. Yan GH, Choi YH. Salidroside attenuates allergic airway inflammation through negative regulation of nuclear factor-kappa B and p38 mitogen-activated protein kinase. J Pharmacol Sci. 2014;126(2):126-135. doi:10.1254/jphs.14037FP
10. Xing S, Yang X, Li W, et al. Salidroside stimulates mitochondrial biogenesis and protects against H₂O₂-induced endothelial dysfunction. Oxid Med Cell Longev. 2014;2014:904834. doi:10.1155/2014/904834
11. Sun YM, Wang XY, Zhou XR, et al. Salidroside ameliorates radiation damage by reducing mitochondrial oxidative stress in the submandibular gland. Antioxidants (Basel). 2022;11(7):1414. doi:10.3390/antiox11071414
12. Hu C, Zhang Q, Chen J, et al. Protective effect of salidroside on mitochondrial disturbances via reducing mitophagy and preserving mitochondrial morphology in OGD-induced neuronal injury. Curr Med Sci. 2021;41(5):936-943. doi:10.1007/s11596-021-2374-6
13. Zhao M, Feng L, Li W. Salidroside: Diverse synthetic pathways and recent advances in pharmacological effects across multiple systems. Pharmacol Res Nat Prod. 2025;6:100176. doi:10.1016/j.prenap.2025.100176
14. Sun D, Peng J, Zhong Q, et al. Anti-inflammatory and antioxidant effects of salidroside in diabetic nephropathy: A systematic review and meta-analysis of preclinical studies. Front Pharmacol. 2026;17:1793037. doi:10.3389/fphar.2026.1793037
15. Guo J, Jiang S, Liu M, et al. Salidroside: A potential drug candidate to treat rheumatoid arthritis. Molecules. 2025;30(19):3865. doi:10.3390/molecules30193865
16. Qin Y, Su J. Salidroside suppresses cell growth and inflammatory response of fibroblast-like synoviocytes via inhibition of phosphoinositol-3 kinase/threonine kinase signaling in rheumatoid arthritis. Z Rheumatol. 2024;83(suppl 1):78-87. doi:10.1007/s00393-023-01431-5